Search by Drug Name or NDC
NDC 16571-0698-09 Lansoprazole 30 mg/1 Details
Lansoprazole 30 mg/1
Lansoprazole is a ORAL CAPSULE, DELAYED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Rising Pharma Holdings, Inc.. The primary component is LANSOPRAZOLE.
MedlinePlus Drug Summary
Prescription lansoprazole is used to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the tube between the throat and stomach) in adults and children 1 year of age and older. Prescription lansoprazole is used to treat the damage from GERD in adults and children 1 year of age and older. Prescription lansoprazole is used to allow the esophagus to heal and prevent further damage to the esophagus in adults with GERD. Prescription lansoprazole is also used to treat ulcers (sores in the lining of the stomach or intestine), to prevent more ulcers from developing in adults whose ulcers have already healed, and to decrease the risk that adults who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) will develop ulcers. Prescription lansoprazole is also used to treat conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome in adults. Prescription lansoprazole is also used in combination with other medications to treat and prevent stomach ulcers caused by a certain type of bacteria (H. pylori) in adults. Nonprescription (over-the-counter) lansoprazole is used to treat frequent heartburn (heartburn that occurs two or more days per week) in adults. Lansoprazole is in a class of medications called proton pump inhibitors. It works by decreasing the amount of acid made in the stomach.
Related Packages: 16571-0698-09Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Lansoprazole
Lansoprazole, clarithromycin, and amoxicillin are used to treat and prevent the return of ulcers (sores in the lining of the stomach or intestine) caused by a certain type of bacteria (H. pylori). Lansoprazole is in a class of medications called proton pump inhibitors. Clarithromycin and amoxicillin are in a class of medications called antibiotics. Lansoprazole works by decreasing the amount of acid made in the stomach. Clarithromycin and amoxicillin work by stopping the growth of the bacteria that may cause ulcers. Antibiotics will not work for colds, flu, or other viral infections.
Related Packages: 16571-0698-09Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Lansoprazole, Clarithromycin, and Amoxicillin
Product Information
| NDC | 16571-0698 |
|---|---|
| Product ID | 16571-698_b62ff2cb-32d6-4056-badb-343f922b3a21 |
| Associated GPIs | 49270040006520 |
| GCN Sequence Number | 030107 |
| GCN Sequence Number Description | lansoprazole CAPSULE DR 30 MG ORAL |
| HIC3 | D4J |
| HIC3 Description | PROTON-PUMP INHIBITORS |
| GCN | 01698 |
| HICL Sequence Number | 008993 |
| HICL Sequence Number Description | LANSOPRAZOLE |
| Brand/Generic | Generic |
| Proprietary Name | Lansoprazole |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Lansoprazole |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE, DELAYED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/1 |
| Substance Name | LANSOPRAZOLE |
| Labeler Name | Rising Pharma Holdings, Inc. |
| Pharmaceutical Class | Inhibition Gastric Acid Secretion [PE], Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA201921 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 16571-0698-09 (16571069809)
| NDC Package Code | 16571-698-09 |
|---|---|
| Billing NDC | 16571069809 |
| Package | 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (16571-698-09) |
| Marketing Start Date | 2020-01-11 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.10942 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | LANSOPRAZOLE DR 30 MG CAPSULE |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |